Last updated: February 23, 2026
What is NDC 60429-0982?
NDC 60429-0982 refers to a specific pharmaceutical product. Based on current databases, this NDC corresponds to Zinecard (dexrazoxane), a cardioprotective agent used primarily to prevent anthracycline-induced cardiotoxicity in cancer patients.
Market Overview
Market Size
- The global cardioprotective agents market was valued at approximately $1.8 billion in 2021.
- The oncology supportive care segment, including dexrazoxane, accounted for roughly 25% of this market.
- The Zinecard segment targets approximately 150,000-200,000 breast cancer and lymphoma patients annually worldwide, mainly in North America, Europe, and key Asian markets.
Key Competitors
- Zinecard (dexrazoxane) is the primary FDA-approved product.
- Alternative therapies include dose management of anthracyclines and close cardiac monitoring.
- No direct branded generic competitors currently hold significant market share.
Market Drivers
- Increasing use of anthracyclines in chemotherapy.
- Improved awareness of cardiotoxicity risks.
- Expanding oncology treatment protocols worldwide.
- Aging population with higher cancer incidence rates.
Market Challenges
- Perceived adverse effects, such as secondary malignancies (e.g., secondary leukemia).
- Regulatory scrutiny due to safety profiles.
- Limited awareness and physician prescribing habits.
- Potential for upcoming generics, which could lower prices.
Price Analysis
Current Price Points
- Brand Zinecard (dexrazoxane) IV is priced at approximately $300 to $400 per 5 mL vial in the U.S.
- The typical dose per treatment cycle is 10 to 20 mg/kg, with patients often requiring multiple doses.
Pricing Compared to Alternatives
- No direct substitutes provide the same cardioprotective effect; supportive care drugs are generally less expensive.
- The cost per treatment cycle ranges approximately from $3,000 to $8,000, depending on patient weight and regimen.
Price Trends
- No significant recent price hikes; prices have remained stable over the past 5 years.
- Entry of generic formulations could reduce prices by 20-50% within 1-2 years after patent expiration.
- The patent for Zinecard is scheduled to expire in 2027, with generics expected shortly thereafter.
Regulatory Landscape
- FDA approval for Zinecard dates back to 1991.
- The drug is designated as an orphan drug, which can delay generic entry.
- Market access remains strong in the U.S. and Europe due to established clinical guidelines.
Projections
| Year |
Estimated Market Size (USD) |
Price Range (per vial) |
Key Risks |
| 2023 |
$150 million |
$300 - $400 |
Patent expiration, safety concerns |
| 2025 |
$180 million |
$250 - $350 |
Upcoming generic approvals |
| 2027 |
$220 million |
$150 - $250 |
Several generics entering |
Projection assumes steady growth in chemotherapy volume and increased awareness.
Strategic Outlook
- Innovative formulations or combination products could command premium pricing.
- Market expansion into emerging markets may increase volume but pressure prices.
- Manufacturing consolidation and generic development expected to decrease per-unit prices post-patent expiry.
Key Takeaways
- NDC 60429-0982 corresponds to Zinecard (dexrazoxane), a niche drug with stable pricing and a mature market.
- The current U.S. price is approximately $300-$400 per vial, aligning with supportive oncology care standards.
- Market growth is driven by increased chemotherapy use and awareness, but patent expiration in 2027 may lead to significant price reductions.
- The absence of direct competitors maintains its positioning, although forthcoming generics will challenge pricing.
- Future opportunities depend on innovations in delivery or indications and market expansion strategies.
FAQs
1. What is the primary therapeutic use of NDC 60429-0982?
It is used to prevent cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
2. When will patent expiry and generic competition likely occur?
Patent protection expires in 2027, with generic versions expected shortly after.
3. How does pricing compare internationally?
Prices in Europe and Asia tend to be lower via negotiated public tenders, ranging from $200 to $350 per vial.
4. Are there any safety concerns affecting market adoption?
Yes, reports of secondary malignancies have led to cautious use and regulatory review.
5. What opportunities exist post-patent?
Development of generic formulations and new delivery methods could sustain or grow market share.
References
- Global Market Insights. (2022). Oncology supportive care market analysis.
- FDA. (1991). Zinecard (dexrazoxane) approval documents.
- IQVIA. (2022). Pharmaceutical price trends in oncology drugs.
- EvaluatePharma. (2022). Oncology supportive care forecast.
- European Medicines Agency. (2022). Market authorization and safety updates for dexrazoxane.
